Castration-Resistant Prostate Cancer: Targeted Therapies

Leo, Silvana; Accettura, Caterina; Lorusso, Vito

doi:10.1159/000323581

Cited by 15 publications

(11 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Growth of early stage PCa is androgen-dependent [132]. The serum prostate-specific antigen test along with digital rectal examination have been widely used in detection of early stage PCa.…”

Section: Mir-141 In Cancer Diagnosis and Prognosismentioning

confidence: 99%

The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment

Gao

Feng²,

Han³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Cancer remains one of the most threatening causes of human health impairment, and the mechanisms underlying tumorigenesis have not been completely characterized. MicroRNAs (miRNAs) are a group of endogenous, small (18∼25 nucleotides) non-coding RNAs which negatively regulate gene expressions by directly binding to the 3'-untranslated regions (3'-UTRs) of the target messenger RNAs (mRNAs). Increasing evidence has demonstrated abnormal miRNA profiles and confirmed their involvement in tumor initiation and progression. As one important member of the miR-200 family, microRNA (miR)-141 is aberrantly expressed in many human malignant tumors, participating in various cellular processes including epithelial-mesenchymal transition (EMT), proliferation, migration, invasion, and drug resistance. In the present review, we briefly describe the mechanisms underlying miR-141-mediated tumorigenesis and the possible future of miR-141 as a potential diagnostic and prognostic parameter as well as therapeutic target in clinical applications.

show abstract

Section: Mir-141 In Cancer Diagnosis and Prognosismentioning

confidence: 99%

The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment

Gao

Feng²,

Han³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…However, our study adds to the body of evidence that combination therapies with docetaxel do not benefit the patient and only increase the risk of (in some cases substantial) side effects [25,26]. …”

Section: Discussionmentioning

confidence: 99%

A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer

et al. 2014

View full text Add to dashboard Cite

Background: Docetaxel plus prednisone is a standard treatment for castration-resistant prostate cancer. Cyclophosphamide may be an effective combination partner. Methods: This randomised, multicentre, phase II trial compared the combination therapy of docetaxel plus prednisone plus cyclophosphamide with the standard therapy of docetaxel plus prednisone. Results: Thirty-three patients received six 3-week treatment cycles (in total 171 cycles). During treatment, an adequate decline in prostate-specific antigen was seen in both groups (p = 0.068) without between-group differences (p = 0.683). No relevant differences between within-group changes were observed for blood pressure, weight, pain score, laboratory variables or quality of life. There were no serious side effects apart from leucopenia requiring treatment (docetaxel + prednisone + cyclophosphamide arm) and no drug-related withdrawals; all three fatalities were considered to be cancer related. Conclusions: The oncological effectiveness and tolerability of docetaxel plus prednisone were supported; an additional effect of cyclophosphamide was not detected. However, the small number of patients and short observation period restrict the generalisability of the results.

show abstract

“…CRPC is a progressive and morbid disease; the median survival of patients is approximately 1 year [3]. The estimated mortality has markedly increased from 7,514 deaths in 2000 to 11,143 in 2012 [4]. …”

Section: Introductionmentioning

confidence: 99%

Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer

et al. 2015

View full text Add to dashboard Cite

Aim: Docetaxel-based chemotherapy against castration-resistant prostate cancer (CRPC) has recently been shown to be effective and tolerable. The objective of this study was to retrospectively evaluate the efficacy and toxicity of low-dose docetaxel in combination with dexamethasone. Methods: Thirty-seven CRPC patients were administered a treatment regimen consisting of 50 mg/m² docetaxel once every 3-4 weeks and 1 mg dexamethasone daily at our institution, between November 2004 and April 2014. Results: Twenty-four patients (65%) had a decrease in serum prostate-specific antigen (PSA) >50%. The median overall survival (OS) and PSA progression-free survival were 26.2 and 10.0 months, respectively. Ten of 12 patients (83%) taking analgesic agents reduced their intake because of decreased pain levels. Grade 3 febrile neutropenia occurred in 2 patients (5%). Nonhematological toxicities were less frequent but sometimes severe. Treatment-related death occurred in 2 octogenarian patients, 1 due to gastric bleeding and the other due to infective endocarditis. Conclusion: Low-dose docetaxel in combination with dexamethasone is feasible in Japanese CRPC patients. Hematological toxicity is less than that seen with standard docetaxel therapy, but it is necessary to monitor patients for severe nonhematological toxicities, particularly very elderly patients.

show abstract

Castration-Resistant Prostate Cancer: Targeted Therapies

Cited by 15 publications

References 112 publications

The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment

The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment

A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer

Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About